These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12662144)

  • 1. Recombinant antibodies for cancer diagnosis and therapy.
    Souriau C; Hudson PJ
    Expert Opin Biol Ther; 2003 Apr; 3(2):305-18. PubMed ID: 12662144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibodies for cancer diagnosis and therapy.
    Hudson PJ; Souriau C
    Expert Opin Biol Ther; 2001 Sep; 1(5):845-55. PubMed ID: 11728219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keystone symposia: antibody-based therapeutics for cancer.
    Power B; Hudson P
    Expert Opin Biol Ther; 2003 Apr; 3(2):385-9. PubMed ID: 12662151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant antibodies: a novel approach to cancer diagnosis and therapy.
    Hudson PJ
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1231-42. PubMed ID: 11060739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant antibody constructs in cancer therapy.
    Hudson PJ
    Curr Opin Immunol; 1999 Oct; 11(5):548-57. PubMed ID: 10508712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of therapeutic antibodies in drug discovery.
    Stockwin LH; Holmes S
    Biochem Soc Trans; 2003 Apr; 31(2):433-6. PubMed ID: 12653655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant antibody fragments.
    Hudson PJ
    Curr Opin Biotechnol; 1998 Aug; 9(4):395-402. PubMed ID: 9720265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting and screening recombinant antibody libraries.
    Hoogenboom HR
    Nat Biotechnol; 2005 Sep; 23(9):1105-16. PubMed ID: 16151404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered antibody fragments and the rise of single domains.
    Holliger P; Hudson PJ
    Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
    Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
    Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, production and evaluation of novel diagnostic and therapeutic reagents. 6-9 December 1999, La Jolla, CA, USA.
    Hudson PJ
    IDrugs; 2000 Mar; 3(3):262-4. PubMed ID: 16103928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies and their fragments as anti-cancer agents.
    Schaedel O; Reiter Y
    Curr Pharm Des; 2006; 12(3):363-78. PubMed ID: 16454750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
    Reiter Y; Brinkmann U; Lee B; Pastan I
    Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant antibodies for the diagnosis and treatment of cancer.
    Krauss J
    Mol Biotechnol; 2003 Sep; 25(1):1-17. PubMed ID: 13679630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating improved single-chain Fv molecules for tumor targeting.
    Adams GP; Schier R
    J Immunol Methods; 1999 Dec; 231(1-2):249-60. PubMed ID: 10648942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of monoclonal antibodies in cancer therapy: present and promise.
    Stern M; Herrmann R
    Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.